At a glance
- Originator GlaxoSmithKline
- Class Antiarrhythmics
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 05 Nov 2002 Discontinued - Phase-II for Arrhythmias in Europe (unspecified route)
- 01 May 2001 Phase-II clinical trials for Arrhythmias in Europe (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline